Skip to main content
Fig. 6 | Biology Direct

Fig. 6

From: MDA19, a novel CB2 agonist, inhibits hepatocellular carcinoma partly through inactivation of AKT signaling pathway

Fig. 6

CB2 knockdown promoted HCC cell mobility and activated AKT signaling pathway NC: HCC cells were transfected with siNC (50nM); CB2-KD: HCC cells were transfected with CB2 siRNA (50nM); MDA19 + CB2-KD: HCC cells were transfected with CB2 siRNA (50nM) and treated with MDA19 (30μM for Hep3B and 40μM for HepG2) for 48 h. a Cell migration and (b) cell invasion were detected by transwell assay. c AKT signaling pathway components, including AKT, p-AKT, CDK4, CDK6 and Cyclin D1, were detected by western blot and analyzed by Image J software. All experiments were performed at 3 times. *P < 0.05

Back to article page